Écrit par GBI Reasearch | 24 Août 2016

London – 22 August 2016 - Although opioids continue to dominate the chronic pain market, adverse events associated with the drug such as the potential for abuse mean the treatment space is rife with unmet needs, which is encouraging pharmaceutical companies to explore innovative alternatives to opioids, according to business intelligence provider GBI Research.

The company’s latest...

Écrit par GBI Research | 21 Août 2016

London –17 August 2016 - The market size for respiratory therapeutics, covering asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and cystic fibrosis, is expected to rise considerably from $28.1 billion in 2015 to $46.6 billion by 2022, at a compound annual growth rate (CAGR) of 7.5%, according to business intelligence provider GBI...

Écrit par Roche | 21 Août 2016

First Lady Margaret Kenyatta inaugurates partnership between government of Kenya and Roche to improve care of women with breast cancer

NAIROBI, Kenya, August 15, 2016/ -- First Lady Margaret Kenyatta, Kenya Ministry of Health and Roche Pharmaceuticals Limited (www.Roche.com) has launched key activities that will facilitate access to improved care for patients with breast cancer in Kenya. The...

Écrit par GlobalData | 07 Août 2016

LONDON, UK (GlobalData), 1 August 2016 - The therapeutics market for venous thromboembolism (VTE), a condition which comprises deep vein thrombosis and pulmonary embolism, is set to rise from $2.8 billion in 2015 to $3.7 billion by 2025, representing a Compound Annual Growth Rate (CAGR) of 2.89%, according to research and consulting firm GlobalData.

The company’s latest report*...